Trexquant Investment LP cut its position in Hologic, Inc. (NASDAQ:HOLX) by 54.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,000 shares of the medical equipment provider’s stock after selling 24,026 shares during the period. Trexquant Investment LP’s holdings in Hologic were worth $908,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Nationwide Fund Advisors increased its stake in shares of Hologic by 11.2% in the first quarter. Nationwide Fund Advisors now owns 511,970 shares of the medical equipment provider’s stock worth $21,784,000 after buying an additional 51,676 shares during the period. State of Alaska Department of Revenue bought a new stake in shares of Hologic during the first quarter worth about $530,000. Nisa Investment Advisors LLC increased its stake in shares of Hologic by 60.9% in the first quarter. Nisa Investment Advisors LLC now owns 86,602 shares of the medical equipment provider’s stock worth $3,685,000 after buying an additional 32,782 shares during the period. DnB Asset Management AS increased its stake in shares of Hologic by 13.4% in the first quarter. DnB Asset Management AS now owns 19,505 shares of the medical equipment provider’s stock worth $830,000 after buying an additional 2,300 shares during the period. Finally, Gateway Investment Advisers LLC increased its stake in shares of Hologic by 12.5% in the first quarter. Gateway Investment Advisers LLC now owns 489,358 shares of the medical equipment provider’s stock worth $20,822,000 after buying an additional 54,208 shares during the period. 94.46% of the stock is owned by institutional investors and hedge funds.

Hologic, Inc. (NASDAQ:HOLX) opened at 38.33 on Thursday. The firm has a 50-day moving average price of $44.21 and a 200 day moving average price of $42.94. The firm has a market capitalization of $10.75 billion, a P/E ratio of 14.28 and a beta of 0.90. Hologic, Inc. has a 52-week low of $35.15 and a 52-week high of $46.80.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.01. The firm had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.51 earnings per share. Analysts forecast that Hologic, Inc. will post $2.01 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.watchlistnews.com/trexquant-investment-lp-sells-24026-shares-of-hologic-inc-holx/1469594.html.

A number of analysts have issued reports on the company. Stifel Nicolaus raised their target price on Hologic from $45.00 to $48.00 and gave the stock a “buy” rating in a research note on Thursday, May 11th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $49.00 target price on shares of Hologic in a research note on Wednesday, June 28th. Bank of America Corporation reaffirmed a “neutral” rating and issued a $48.00 target price (up from $44.00) on shares of Hologic in a research note on Friday, July 21st. Canaccord Genuity reaffirmed a “buy” rating and issued a $53.00 target price on shares of Hologic in a research note on Tuesday, May 9th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $51.00 target price on shares of Hologic in a research note on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $48.64.

In other Hologic news, Director Lawrence M. Levy sold 9,076 shares of the company’s stock in a transaction dated Wednesday, May 17th. The stock was sold at an average price of $42.80, for a total transaction of $388,452.80. Following the completion of the sale, the director now directly owns 43,165 shares in the company, valued at $1,847,462. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Elaine Ullian sold 8,938 shares of the company’s stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $43.99, for a total value of $393,182.62. Following the sale, the director now owns 23,810 shares of the company’s stock, valued at $1,047,401.90. The disclosure for this sale can be found here. Insiders have sold 60,627 shares of company stock valued at $2,632,911 over the last 90 days. 0.79% of the stock is currently owned by insiders.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.